Area of research
Oncology · Molecular Biology
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Cancer therapeutics and mechanisms, and Lung Cancer Treatments and Mutations.
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i> <i>V600</i> -Mutated Melanoma
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.
Supplementary Fig. S7 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Data from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S6 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Table S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S5 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S4 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Table S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S5 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S7 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Table S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S6 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Fig. S4 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Data from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Table S1 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Table S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Supplementary Table S3 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i><sup><i>V600</i></sup>-Mutated Melanoma
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide